Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT00177216
Other study ID # R01MH024652
Secondary ID 010807DATR A2-AI
Status Active, not recruiting
Phase Phase 4
First received September 12, 2005
Last updated April 30, 2009
Start date February 2002

Study information

Verified date April 2009
Source National Institute of Mental Health (NIMH)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

This study will compare the symptoms, experiences, and laboratory sleep characteristics of young adults with and without insomnia.


Description:

The overall aim of this research study is to compare the symptoms, experiences and laboratory sleep characteristics of young adults with and without insomnia. Insomnia is a pattern of difficulty falling asleep, staying asleep or feeling poorly rested despite an adequate amount of time for sleep, which occurs nearly every night for one month or longer. For those with insomnia, we will look at the effects of an intervention with one of two medications (escitalopram or zolpidem) or an inactive pill (placebo). This intervention will be followed by re-evaluation of symptoms, experiences and laboratory sleep characteristics. The three hypotheses being investigated are: compared to control subjects, those with insomnia will demonstrate affective disturbance and heightened arousal; the different medications will have different degrees of effect on the two dimensions being measured (affective disturbance and heightened arousal); and PET scans will reveal different patterns of activity in the brains of groups of people with insomnia.

We will specifically focus on the syndrome of Primary Insomnia (PI), defined by DSM-IV as insomnia that lasts for at least one month and causes significant impairment or distress. PI excludes insomnia that occurs exclusively during the course of another sleep, mental, substance-induced, or medical disorder. Insomnia is a significant public health problem because of its prevalence, morbidity, and the risk it poses for the development of subsequent mental disorders, particularly depressive and anxiety disorders. Understanding the psychobiology of primary insomnia is a critical step toward addressing questions regarding its relationships with mood and anxiety disorders.

Our model of insomnia builds on two major concepts running through previous insomnia research, affective disturbance and heightened arousal, as driving factors for the sleep-wake disturbances that define PI. Implicit in this model is that individuals with PI have different degrees of each dysfunction, which accounts for their heterogeneity of clinical symptoms. Contemporary theories of affect structure suggest that these two dimensions may be orthogonal in pure form, but are nevertheless related in clinical conditions characterized by mixed anxiety-depression, such as PI. Measures of affective disturbance and arousal in this study will include questionnaires, diary-based assessments, and physiological measures.

Pharmacological treatment probes may help to further distinguish the roles of affective disturbance and heightened arousal in insomnia. We will use a benzodiazepine receptor agonist (BzRA), zolpidem, and an antidepressant, escitalopram. BzRA potentiate the effects of GABA (1), but have minimal direct activity at any other receptor types. They are efficacious treatments for insomnia (2-4), but have little effect on mood. We chose zolpidem because it is relatively specific for hypnotic versus anxiolytic or other actions (5), because it is the most widely-prescribed BzRA hypnotic, and because it is well-tolerated (6). Clinically-effective doses of even "nonsedating" antidepressants can also improve symptoms in PI (7), suggesting that direct sedation is not their only mechanism for improving insomnia. We chose escitalopram because it is neither strongly alerting nor sedating in clinical and polysomnographic studies. This "sleep-neutral" profile will allow us to use it for its effects on affective disturbance, rather than its nonspecific sedating properties. Escitalopram's specific effect on serotonin reuptake blockade and its lack of affinity for Bz receptors distinguish it from zolpidem as a pharmacologic probe.

Functional neuroimaging studies in wakefulness and sleep may also help to identify the substrate of affective disturbance and heightened arousal in insomnia. Affective disturbance in the form of MDD is associated with alterations in both regional deactivation patterns during NREM sleep, and regional activation patterns during REM sleep. These observations suggest that a sleep-wake functional neuroimaging paradigm in insomnia patients, in conjunction with behavioral measures, may help to identify which brain systems mediate heightened arousal and affective disturbance, and how these systems interact.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 99
Est. completion date
Est. primary completion date May 2008
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 20 Years to 50 Years
Eligibility Inclusion Criteria:

- Physically healthy

- Meets DSM-IV criteria for primary insomnia

- For subjects interested in PET study only: right-handedness

Exclusion Criteria:

- Currently taking antidepressants, antianxiety medications or medications for sleep disorders

- Currently experiencing symptoms of psychiatric disorders such as major depressive disorder, bipolar disorder, generalized anxiety disorder

- Significant or unstable acute or chronic medical conditions, such as seizure disorder, tumor, liver disease, active peptic ulcer disease, arthritis, irritable bowel disease

- Meets DSM-IV criteria for sleep apnea or periodic limb movement disorder

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Escitalopram
Antidepressant, escitalopram, treatment for insomnia
Zolpidem
Benzodiazepine receptor agonist (BzRA), zolpidem, treatment for insomnia
Placebo
Placebo control

Locations

Country Name City State
United States Western Psychiatric Institute and Clinic/ University of Pittsburgh Medical Center Pittsburgh Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pittsburgh Sleep Quality Index score, Sleep Diary data, and polysomnographic sleep studies Measured at baseline and Week 9 No
Secondary Self-report sleep diaries, improvement scales, Pittsburgh Insomnia Rating Scale, Arousal Predisposition Scale, and the Inventory of Depressive Symptomatology Measured weekly for 9 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02188498 - Electrocardiography Data Analysis in Sleep Disorders
Completed NCT00990106 - Augmentation Trial of Prazosin for Post-Traumatic Stress Disorder (PTSD) N/A
Completed NCT00942253 - Exercise Training in Dialysis Patients With Restless Legs Syndrome (RLS) Phase 2
Completed NCT00163670 - The Impact of Sleep Disorders on Motor Vehicle Accidents N/A
Completed NCT00203827 - Pediatric Sleep Questionnaire: Use for Collection of Clinical Data N/A
Completed NCT00256685 - Study Evaluating DVS-233 SR to Treat Vasomotor Systems Associated With Menopause Phase 3
Completed NCT00174174 - Provigil (Modafinil) Study by Taiwan Biotech Co. N/A
Terminated NCT00750919 - Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007) Phase 3
Completed NCT03075241 - Z-Drugs for Sleep Disorders in Alzheimer's Disease Phase 3
Completed NCT02939586 - The Effect of Haemodialysis in Sleep Apnoea N/A
Completed NCT02585609 - Sleep Quality in Patients With Advanced Cancer N/A
Completed NCT03055156 - Effect of High Rebound Mattress Toppers on Sleep and Sleep-Related Symptoms N/A
Completed NCT02156128 - Subjective Memory Complaints, Objective Memory Performance and Cognitive Training N/A
Completed NCT01929447 - Evaluation of WP200 With the Unified Probe (WP200U) N/A
Completed NCT01906866 - Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities Phase 3
Completed NCT01528462 - Sleep Disorders Managed and Assessed Rapidly in Transient Ischemic Attack (TIA) and In Early Stroke
Completed NCT01256983 - Light for Renal Transplant Recipients Having a Sleep-Wake Dysregulation Phase 0
Completed NCT01220401 - Efficacy of a Brief Nightmare Treatment for Veterans N/A
Not yet recruiting NCT00749814 - Sleep Disturbances in Hospitalized Children Phase 4
Completed NCT00518986 - Efficacy and Safety of Armodafinil for Adults With Excessive Sleepiness Obstructive Sleep Apnea/Hypopnea and Depression Phase 4